The effect of intravitreal recombinant tissue plasminogen activator injection on diabetic tractional fibrovascular membranes: Proposed criteria using optical coherence tomography. Issue 1 (January 2022)

• Record Type: Journal Article
• Authors: Ghasemi Falavarjani, Khalil; Anvari, Pasha; Dehghan Niri, Mohammadhasan; Molaei, Saber; Abdi, Fateme; Shad, Esrafil; Kazemi, Pegah; Sadda, SriniVas R
• Is Part Of: European journal of ophthalmology. Volume 32:Issue 1(2022)
• Page Start: 424
• Page End: 428
• Publication Date: 2022-01
• Subjects: Optical coherence tomography -- proliferative diabetic retinopathy -- recombinant tissue plasminogen activator -- tractional retinal detachment; Ophthalmology -- Periodicals; Eye -- Diseases -- Periodicals; 617.7005
• DOI: 10.1177/1120672121998224
• Languages: English
• ISSNs: 1120-6721

Abstract

Purpose: To evaluate the effect of intravitreal recombinant tissue plasminogen activator (tPA) on diabetic tractional fibrovascular membranes (FVM) using proposed optical coherence tomography (OCT) criteria. Methods: This prospective, interventional case series enrolled eyes with tractional retinal detachment who were candidates for pars plana vitrectomy. OCT images were obtained to evaluate the border of the attached–detached retina and overlying FVP at baseline and 1 week post-intravitreal tPA injection using the follow-up scan acquisition protocol. Two independent graders assessed retinal detachment (RD) height, FVM height, and retinal thickness at the site of membrane attachment. Results: Thirteen eyes from 13 individuals were included. Assessment of RD height, FVM height, and retinal thickness at membrane attachment point were feasible at both visits in 10/13 (77%), 10/13 (77%), and 8/13 (62%) of eyes, respectively. There was excellent agreement between the two graders for all measurements (all ICC > 0.94). Release of the retina-membrane attachment point was not observed in any eyes. No statistically significant change was found in any of the measured parameters. Conclusions: Excellent agreement was achieved between the graders for quantitative assessment of diabetic FVM using our proposed OCT criteria. We did not observe a significant change in the FVM measurements, 1-week after intravitreal tPA injection.